98%
921
2 minutes
20
Vascular pathology of the lower limbs is a widespread disease affecting the quality of life for more than 30% of the adult world population. Polydocanol foam is presently the main therapeutic option for treating varicosities, inflammation, and chronic disease which affect the vascular endothelium and blood vessels. Unfortunately, the commercial product contains detergents and surfactants which can provoke several side effects and decrease the efficacy of therapy. In an attempt to overcome these drawbacks, polydocanol foam was mixed with different liposomes before use. The resulting mixture was stable and generated supramolecular nanoconstructs, which may prevent the interaction of the components of the commercial polydocanol foam with the vascular endothelium. This effect depends on the presence of liposomes, which can induce polydocanol foam to change its structure from micelles to complex nanostructures, thus improving its stability. In this attempt, the physicochemical features of the resulting nanoconstructs were tested through dynamic- and multiple light scattering analyses, rheological studies and gel permeation chromatography, while the stability was tested in biological fluids. Our preliminary results showed that the nanoconstructs have some potential as therapeutic agents in sclerotherapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.colsurfb.2018.12.027 | DOI Listing |
Ann Vasc Surg
August 2025
State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Department of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China. Electronic address:
Background: Low-flow vascular malformations (LFVMs), encompassing venous, lymphatic, and capillary malformations, are congenital vascular anomalies marked by abnormal vascular or lymphatic development and low-flow hemodynamics. Sclerotherapy has become the primary treatment due to its minimally invasive nature and high efficacy. This review aims to outline the clinical applications, mechanisms, and outcomes of commonly used sclerosants for LFVMs.
View Article and Find Full Text PDFUpdates Surg
August 2025
Department of General Surgery, Azienda Sanitaria Locale ASL Lecce, Casarano, Italy.
JAMA Otolaryngol Head Neck Surg
August 2025
Department of Otolaryngology-Head and Neck Surgery, Washington University in St Louis School of Medicine, St Louis, Missouri.
Importance: Sclerotherapy involves injecting a sclerosing agent into the nasal, oral mucosa, and cutaneous telangiectasias to reduce bleeding, demonstrating both safety and efficacy as a treatment. Despite its proven benefits, few physicians currently offer this therapy to patients with hereditary hemorrhagic telangiectasia (HHT).
Objective: To promote the safe use of sclerotherapy among patients with HHT.
Updates Surg
August 2025
Department of General Surgery, Azienda Sanitaria Locale ASL Lecce, Casarano, Italy.
J Anus Rectum Colon
July 2025
Proctology Department, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Objectives: The aim of this study was to evaluate the effectiveness of injectable sclerotherapy using Polidocanol foam in patients with hemorrhoids and severe anemia during a 1-year follow-up period, while utilizing the Hemorrhoidal Disease Severity Score (HDSS) in conjunction with Short Health Scale (SHS) for assessment.
Methods: A retrospective analysis was conducted on patients with severe anemia and hemorrhoids who underwent injectable sclerotherapy using Polidocanol foam between February 2022 and May 2023.
Results: The bleeding symptoms in all patients resolved immediately after treatment.